Skip to main content
HYUNDAI PHARMACEUTICAL CO., LTD logo

HYUNDAI PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 004310 ISIN · KR7004310009 KO Manufacturing
Open in API
Filings indexed 184 across all filing types
Latest filing 2019-04-18 Major Shareholding Noti…
Country KR South Korea
Listing KO 004310

About HYUNDAI PHARMACEUTICAL CO., LTD

http://www.hyundaipharm.co.kr/english

HYUNDAI PHARMACEUTICAL CO., LTD. is a company engaged in the research, development, manufacturing, and distribution of pharmaceutical products, medical devices, and health-focused food and beverages. The company's portfolio encompasses a broad range of prescription (ETC) and over-the-counter (OTC) medicines. Key therapeutic areas include dermatology, respiratory and gastrointestinal disorders, as well as treatments for conditions such as hypertension and dementia. With a strong commitment to innovation, the company focuses on the research of new substances and the continuous development of its drug pipeline. It also serves as a strategic partner for global companies, facilitating market entry and collaboration through its business development initiatives.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties (e.g., Lee Han-gu, Lee Sang-jun). This type of filing is specifically used to notify the market when a significant shareholder's stake crosses certain thresholds or changes, which falls under the 'Major Shareholding Notification' category.
2019-04-18 Korean
분기보고서 (2019.02)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Hyundai Pharm Co., Ltd. for the first quarter of the 56th fiscal year (covering Dec 1, 2018, to Feb 28, 2019). It contains detailed financial data, business operations, management discussion, and organizational information, which fits the definition of an Interim/Quarterly Report (IR). Q1 2019
2019-04-15 Korean
공정거래자율준수프로그램운영현황(안내공시)
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from Hyundai Pharm regarding their 'Compliance Program (CP)' operations, detailing past performance and future plans. It is a standard corporate disclosure filed with a regulatory body (indicated by the '공정거래 자율준수프로그램 운영현황(안내공시)' header). Since it does not fit into specific categories like financial reports, M&A, or shareholder voting, it falls under the general regulatory filing category.
2019-03-04 Korean
[기재정정]감사보고서 (2018.11)
Audit Report / Information Classification · 100% confidence The document is a 'Correction Report' (정정신고) for an 'Audit Report' (감사보고서) filed by Hyundai Pharm Co., Ltd. It includes the auditor's report, financial statements (Balance Sheet, Income Statement, Statement of Changes in Equity, Cash Flow Statement), and detailed notes to the financial statements. Since it contains the full audited financial statements for the fiscal year, it is classified as an Audit Report (AR). FY 2018
2019-02-28 Korean
사업보고서 (2018.11)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Hyundai Pharm Co., Ltd. covering the 55th fiscal period (2017-12-01 to 2018-11-30). It contains comprehensive financial data, management discussion, business operations, and governance information, which is the standard format for an Annual Report in the Korean regulatory context (DART). It is not an announcement or a summary, but the full report itself. FY 2018
2019-02-28 Korean
감사보고서 (2018.11)
Audit Report / Information Classification · 95% confidence The document is a formal 'Audit Report' (감사보고서) for Hyundai Pharm Co., Ltd. for the fiscal year ending November 30, 2018. It includes the independent auditor's opinion, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. This is a comprehensive financial audit document, not an annual report (10-K) which typically includes management discussion and analysis, business overview, and other non-financial disclosures, nor is it an earnings release or a simple announcement. It fits the definition of an Audit Report (AR). FY 2018
2019-02-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.